Misplaced Pages

Revision as of 16:45, 2 June 2015

Acute erythroid leukemia or Di Guglielmo syndrome is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is of erythroblastic precursors. It is defined as type "M6" under the FAB classification.

Signs and symptoms

The most common symptoms of AEL are related to pancytopenia (a shortage of all types of blood cells), including fatigue, infections, and mucocutaneous bleeding. Almost half of people with AEL exhibit weight loss, fever and night sweats at the time of diagnosis. Almost all people with AEL are anemic, and 77% have a hemoglobin level under 10.0 g/dl. Signs of thrombocytopenia are found in about half of people with AEL.

Causes

The bone marrow creates cells that become leukemic white blood cells.

Diagnosis

Acute erythroid leukemias can be classified as follows:

M6a (Erythroleukemia)

50% or more of all nucleated bone marrow cells are erythroblasts, Dyserythropoiesis is prominent and 20% or more of the remaining cells (non- erythroid) are myeloblasts.

M6b (Pure erythroid leukemia)

In rare cases the erythroid lineage is the only obvious component of an acute leukemia; a myeloblast component is not apparent. The erythroid component consists predominantly or exclusively of proerythroblasts and early basophilic erythroblasts. These cells may constitute 90% or more of the marrow elements. Despite this lack of myeloblasts, these cases should be considered acute leukemias. In a WHO proposal the blastic leukemias that are limited to the erythroid series are designated pure erythroid malignancies.

M6c (Erythroleukemia and Pure erythroid leukemia)

Myeloblast- and proerythroblast-rich mixed variant.

Treatment

Treatment for erythroleukemia generally follows that for other types of AML, not otherwise specified. It consists of chemotherapy, frequently consisting of cytarabine, daunorubicin, and idarubicin. It can also involve bone marrow transplantation.

Prognosis

Information on prognosis is limited by the rarity of the condition. Prognosis appears to be no different to AML in general, taking into account other risk factors. Acute erythroid leukemia (M6) has a relatively poor prognosis. A 2010 study of 124 patients found a median overall survival of 8 months. A 2009 study on 91 patients found a median overall survival for erythroleukemia patients of 36 weeks, with no statistically significant difference to other AML patients. AEL patients did have a significantly shorter disease free survival period, a median of 32 weeks, but this effect was explained by other prognostic factors. That is, AEL is often associated with other risk factors, like monosomal karyotypes and a history of myelodysplastic syndrome. Prognosis is worse in elderly patients, those with a history of myelodysplastic syndrome, and in patients who had previously received chemotherapy for the treatment of a different neoplasm.

Epidemiology

Acute erythroid leukemia is rare, accounting for only 3–5% of all acute myeloid leukemia cases. One study estimated an occurence rate of 0.077 cases per 100,000 people each year. 64–70% of people with this condition are male, and most are elderly, with a median age of 65.

History

The first known case of acute erythroid leukemia was described in 1912 by M. Copelli under the name erythromatosis. In 1917, Italian hematologist Giovanni Di Guglielmo expanded on the description, coining the name "eritroleucemia" (Italian for erythroleukemia). Di Guglielmo was the first to recognize the leukemic nature of the condition, and it is sometimes referred to as Di Guglielmo's syndrome in recognition of his work.

References

1. ^ "Acute erythroid leukemia". Arch. Pathol. Lab. Med. 134 (9): 1261–70. 2010. doi:10.1043/2009-0350-RA.1. PMID 20807044. {{cite journal}}: Unknown parameter |authors= ignored (help)
2. ^ "Acute erythroleukemia: diagnosis and management". Expert Rev Hematol. 3 (6): 705–18. 2010. doi:10.1586/ehm.10.62. PMID 21091147. {{cite journal}}: Unknown parameter |authors= ignored (help)
3. Naeim, Faramarz; Rao, P. Nagesh; Grody, Wayne W. (2009-03-05). Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. Academic Press. ISBN 9780080919485.
4. Schwab, Manfred (2011-09-23). Encyclopedia of Cancer. Springer Science & Business Media. p. 1313. ISBN 9783642164828.
5. Cheng, Liang; Bostwick, David G. (2011-03-18). Essentials of Anatomic Pathology. Springer Science & Business Media. p. 764. ISBN 9781441960436.
6. Armitage, James O. (2004). Atlas of Clinical Hematology. Lippincott Williams & Wilkins. p. 148. ISBN 9780781751285.
7. Raghavan, Derek; Brecher, Martin L.; Johnson, David H.; Meropol, Neal J.; Moots, Paul L.; Rose, Peter G. (2006-07-11). Textbook of Uncommon Cancer. John Wiley & Sons. p. 546. ISBN 9780470030554.
8. Erythroleukemia ~treatment at eMedicine
9. Santos FP, Faderl S, Garcia-Manero G; et al. (December 2009). "Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution". Leukemia. 23 (12): 2275–80. doi:10.1038/leu.2009.181. PMID 19741728.{{cite journal}}: CS1 maint: multiple names: authors list (link)
10. ^ "Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification". Blood. 115 (10): 1985–92. 2010. doi:10.1182/blood-2009-09-243964. PMC 2942006. PMID 20040759. {{cite journal}}: Unknown parameter |authors= ignored (help)
11. Santos FP, Faderl S, Garcia-Manero G; et al. (December 2009). "Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution". Leukemia. 23 (12): 2275–80. doi:10.1038/leu.2009.181. PMID 19741728.{{cite journal}}: CS1 maint: multiple names: authors list (link)
12. Orazi, Attilio; O'Malley, Dennis P.; Arber, Daniel A. (2006-07-20). Illustrated Pathology of the Bone Marrow. Cambridge University Press. p. 59. ISBN 9781139455527.
13. "Erythroleukaemia in the north of England: a population based study". J. Clin. Pathol. 54 (8): 608–12. 2001. doi:10.1136/jcp.54.8.608. PMC 1731487. PMID 11477115. {{cite journal}}: Unknown parameter |authors= ignored (help)
14. "Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease". Mod. Pathol. 23 (8): 1113–26. 2010. doi:10.1038/modpathol.2010.96. PMID 20473273. {{cite journal}}: Unknown parameter |authors= ignored (help)
15. Di Guglielmo G. (1917). "Richerche di ematologia. I. Un caso di eritroleucemia. Megacariociti in circolo e loro funzione piastrinopoietico". Folia Medica (Pavia). 13: 386.

External links

• Kowal-Vern A, Mazzella FM, Cotelingam JD, Shrit MA, Rector JT, Schumacher HR (2000). "Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases". Am. J. Hematol. 65 (1): 5–13. doi:10.1002/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U. PMID 10936857.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Histology at University of Virginia
• Overview at Marist College
• Images at Nagoya University

• Acute myeloid leukemia